Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924713 | 1.00 | F2 (0.80) | F2PRSS1 | |
| SCHEMBL6921055 | 0.88 | F2 (1.00) | F2PRSS1 | |
| SCHEMBL6924895 | 0.88 | F2 (1.00) | F2PRSS1 | |
| SCHEMBL6927348 | 0.88 | F2 (0.77) | F2PRSS1 | |
| SCHEMBL6925267 | 0.85 | F2 (0.79) | F2PRSS1 | |
| SCHEMBL6925084 | 0.83 | F2 (0.76) | F2PRSS1 | |
| SCHEMBL6925090 | 0.83 | F2 (0.76) | F2PRSS1 | |
| SCHEMBL6921669 | 0.82 | F2 (1.00) | F2PRSS1 | |
| SCHEMBL6925190 | 0.81 | F2 (1.00) | F2PRSS1 | |
| SCHEMBL7380149 | 0.79 | F2 (0.51) | F2PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002050056-A1 | BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | F2 2/4885PRSS1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.